Exploring Prognosis-Associated Biomarkers of Estrogen-Independent Uterine Corpus Endometrial Carcinoma by Bioinformatics Analysis

References

• Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. doi:10.1016/S0140-6736(15)00130-0
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B. Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol. 2013;37(4):374–377. doi:10.1016/j.canep.2013.03.008
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. doi:10.1016/0090-8258(83)90111-7
   PubMed Web of Science ®Google Scholar
• Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000;7(4):227–242. doi:10.1677/erc.0.0070227
   PubMed Web of Science ®Google Scholar
• Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol. 2012;24(5):554–563. doi:10.1097/CCO.0b013e328354e585
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–43. doi:10.1016/S0020-7292(06)60031-3
   PubMed Web of Science ®Google Scholar
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol. 2015;117(3):559–581. doi:10.1016/j.radonc.2015.11.013
   PubMed Web of Science ®Google Scholar
• Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol. 2011;54(2):278–291. doi:10.1097/GRF.0b013e318218c755
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–2618. doi:10.1200/JCO.2012.48.2596
   PubMed Web of Science ®Google Scholar
• Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol. 2010;27(4):261–273. doi:10.1053/j.semdp.2010.09.003
   PubMed Web of Science ®Google Scholar
• Hussein YR, Soslow RA. Molecular insights into the classification of high-grade endometrial carcinoma. Pathology. 2018;50(2):151–161. doi:10.1016/j.pathol.2017.09.010
   PubMed Web of Science ®Google Scholar
• Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135(2):184–189. doi:10.1016/j.ygyno.2014.06.033
   PubMed Web of Science ®Google Scholar
• Remmerie M, Janssens V. Targeted therapies in type II endometrial cancers: too little, but not too late. Int J Mol Sci. 2018;19(8):2380. doi:10.3390/ijms19082380
   PubMed Web of Science ®Google Scholar
• Oza AM, Pignata S, Poveda A, et al. Randomized Phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33(31):3576–3582. doi:10.1200/JCO.2014.58.8871
   PubMed Web of Science ®Google Scholar
• Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–253. doi:10.1016/j.ygyno.2014.12.019
   PubMed Web of Science ®Google Scholar
• Powell MA, Sill MW, Goodfellow PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014;135(1):38–43. doi:10.1016/j.ygyno.2014.07.083
   PubMed Web of Science ®Google Scholar
• Lee PS, Secord AA. Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway. Cancer Treat Rev. 2014;40(4):507–512. doi:10.1016/j.ctrv.2013.11.004
   PubMed Web of Science ®Google Scholar
• Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–1323. doi:10.1001/jamaoncol.2015.2151
   PubMed Web of Science ®Google Scholar
• Duran-Sanchon S, Moreno L, Auge JM, et al. Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer. Gastroenterology. 2020;158(4):947–957.e4. doi:10.1053/j.gastro.2019.10.005
   PubMed Web of Science ®Google Scholar
• Polano M, Chierici M, Dal Bo M, et al. A pan-cancer approach to predict responsiveness to immune checkpoint inhibitors by machine learning. Cancers (Basel). 2019;11(10):1562. doi:10.3390/cancers11101562
   PubMed Web of Science ®Google Scholar
• Zhang K, Li H, Yan Y, et al. Identification of key genes and pathways between type I and type II endometrial cancer using bioinformatics analysis. Oncol Lett. 2019;18(3):2464–2476. doi:10.3892/ol.2019.10550
   PubMed Web of Science ®Google Scholar
• Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233–244. doi:10.1002/pro.3307
   PubMed Web of Science ®Google Scholar
• Zhao Y, Du T, Du L, et al. Long noncoding RNA LINC02418 regulates MELK expression by acting as a ceRNA and may serve as a diagnostic marker for colorectal cancer. Cell Death Dis. 2019;10(8):568. doi:10.1038/s41419-019-1804-x
   PubMed Web of Science ®Google Scholar
• Tian J, Cui P, Li Y, et al. LINC02418 promotes colon cancer progression by suppressing apoptosis via interaction with miR-34b-5p/BCL2 axis. Cancer Cell Int. 2020;20:460. doi:10.1186/s12935-020-01530-2
   PubMed Web of Science ®Google Scholar
• Han B. LncRNA LINC02418 regulates proliferation and apoptosis of non-small cell lung cancer cells by regulating miR-4677-3p/SEC61G. Eur Rev Med Pharmacol Sci. 2019;23(23):10354–10362. doi:10.26355/eurrev_201912_19673
   PubMed Web of Science ®Google Scholar
• Wang T, Zhai R, Lv X, Wang K, Xu J. LINC02418 promotes malignant behaviors in lung adenocarcinoma cells by sponging miR-4677-3p to upregulate KNL1 expression. BMC Pulm Med. 2020;20(1):217. doi:10.1186/s12890-020-01229-0
   PubMed Web of Science ®Google Scholar
• Feig LA. Regulation of neuronal function by Ras-GRF exchange factors. Genes Cancer. 2011;2(3):306–319. doi:10.1177/1947601911408077
   PubMedGoogle Scholar
• Calvo F, Sanz-Moreno V, Agudo-Ibanez L, et al. RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation. Nat Cell Biol. 2011;13(7):819–826. doi:10.1038/ncb2271
   PubMed Web of Science ®Google Scholar
• Takamaru H, Yamamoto E, Suzuki H, et al. Aberrant methylation of RASGRF1 is associated with an epigenetic field defect and increased risk of gastric cancer. Cancer Prev Res (Phila). 2012;5(10):1203–1212. doi:10.1158/1940-6207.CAPR-12-0056
   PubMed Web of Science ®Google Scholar
• Sato T, Yoneyama T, Tobisawa Y, et al. Core 2 beta-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. Biochem Biophys Res Commun. 2016;470(1):150–156. doi:10.1016/j.bbrc.2016.01.011
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Kyan A, Yamamoto H, et al. Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int J Cancer. 2010;127(5):1052–1059. doi:10.1002/ijc.25117
   PubMed Web of Science ®Google Scholar
• Tsuboi S, Hatakeyama S, Ohyama C, Fukuda M. Two opposing roles of O-glycans in tumor metastasis. Trends Mol Med. 2012;18(4):224–232. doi:10.1016/j.molmed.2012.02.001
   PubMed Web of Science ®Google Scholar
• Tsuboi S, Sutoh M, Hatakeyama S, et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 2011;30(15):3173–3185. doi:10.1038/emboj.2011.215
   PubMed Web of Science ®Google Scholar
• Seagle BL, Eng KH, Yeh JY, et al. Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Sci Rep. 2016;6:21591. doi:10.1038/srep21591
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–480. doi:10.1016/j.cell.2006.10.018
   PubMed Web of Science ®Google Scholar
• Santiago L, Daniels G, Wang D, Deng FM, Lee P. Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res. 2017;7(6):1389–1406.
   PubMed Web of Science ®Google Scholar
• Shelton DN, Fornalik H, Neff T, et al. The role of LEF1 in endometrial gland formation and carcinogenesis. PLoS One. 2012;7(7):e40312. doi:10.1371/journal.pone.0040312
   PubMed Web of Science ®Google Scholar
• Huang X, Zhong R, He X, et al. Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/beta-catenin signaling. IUBMB Life. 2019;71(2):223–234. doi:10.1002/iub.1959
   PubMed Web of Science ®Google Scholar
• Wu X, Han Y, Liu F, Ruan L. Downregulations of miR-449a and miR-145-5p act as prognostic biomarkers for endometrial cancer. J Comput Biol. 2020;27(5):834–844. doi:10.1089/cmb.2019.0215
   PubMed Web of Science ®Google Scholar
• Hu S, Zheng Q, Wu H, Wang C, Liu T, Zhou W. miR-532 promoted gastric cancer migration and invasion by targeting NKD1. Life Sci. 2017;177:15–19. doi:10.1016/j.lfs.2017.03.019
   PubMed Web of Science ®Google Scholar
• Cui Y, Gao D, Linghu E, et al. Epigenetic changes and functional study of HOXA11 in human gastric cancer. Epigenomics. 2015;7(2):201–213. doi:10.2217/epi.14.92
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Y, Dai SD, Wang EH. Down-regulation of NKD1 increases the invasive potential of non-small-cell lung cancer and correlates with a poor prognosis. BMC Cancer. 2011;11:186. doi:10.1186/1471-2407-11-186
   PubMed Web of Science ®Google Scholar
• Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res. 2005;11(12):4295–4304. doi:10.1158/1078-0432.CCR-04-1162
   PubMed Web of Science ®Google Scholar